KDTV001 Injection in Patients With Human Papillomavirus (HPV) Types 16, and/or 18, and/or 52 Associated Cervical High-Grade Squamous Intraepithelial Lesion .

KDTV001 Injection is a non-replicating adenovirus serotype 5 (Ad5)-based therapeutic HPV vaccine developed by Wuhan KadGeno Biotechnology Co., Ltd. It utilizes an engineered adenoviral vector expressing the HPV16/18/52 E6/E7 fusion protein under CMV promoter control, designed to inducing a robust cellular immune response that eradicates HPV-related lesions. This is a Phase I, multicenter, open-label, dose-escalation and expansion study to evaluate the safety, tolerability, immunogenicity, and preliminary efficacy of KDTV001 Injection in participants with HPV types 16, and/or 18, and/or 52-ass

Trial Details

NCT ID
NCT07948083
Phase
PHASE1 / PHASE2
Sponsor
Wuhan KadGeno Biotechnology Co., Ltd
Status
RECRUITING
Cancer Type
Squamous Cell Cervical Cancer
Interventions
  • KDTV001
Locations (sample)
  • Wuhan, Hubei, China|30.58333,114.26667
  • Wuhan, Hubei, China|30.58333,114.26667

Key Eligibility Criteria

  • Cervical HSIL (defined as CIN 2 or 3), with the histological diagnosis confirmed by central pathology review within 12 weeks before the first study…
  • Confirmed cervical infection with HPV types 16, and/or 18, and/or 52 at screening by Central Lab. If there are other high-risk types of HPV infecti…
  • All participants must have lesions of adequate size to ensure that a visible lesion remains after the screening biopsy.
  • Participants must have satisfactory colposcopy at screening, defined as full visualization of entire lesion and the squamo-columnar junction (Type …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Squamous Cell Cervical Cancer Trials on Trialify →